secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2025-03-28T23:59:59+00:00
Accession:  0001104659-25-029124
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

European Commission refuses renewal of Translarna (ataluren) marketing authorization in EU
--------------------------------------------------------------------------------

- EC adopted CHMP negative opinion; renewal of conditional MA for nonsense mutation DMD denied.
- Drug effectively removed from European Economic Area; authorization ends.
- EC indicated EU member states may allow continued use under Articles 117(3) and 5(1) of Directive 2001/83.
- PTC CEO expresses disappointment; plans to work country-by-country to maintain commercial access.
- Decision based on CHMP conclusion that efficacy was not established and benefit-risk not confirmed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000110465925029124/0001104659-25-029124-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000110465925029124/tm2510789d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-029124

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer